Zhang P, Li B, Wang Y, Min W, Wang X, Zhou Y
BMC Microbiol. 2022; 22(1):42.
PMID: 35114938
PMC: 8811342.
DOI: 10.1186/s12866-022-02450-z.
Patel S, Jallow S, Boiditswe S, Madhi S, Feemster K, Steenhoff A
J Pediatric Infect Dis Soc. 2019; 9(3):349-356.
PMID: 31549157
PMC: 7358043.
DOI: 10.1093/jpids/piz056.
Nishimura H, Sato K, Ngako Kadji F, Ohmiya S, Ito H, Kubo T
J Thorac Dis. 2018; 10(5):E322-E327.
PMID: 29997985
PMC: 6006084.
DOI: 10.21037/jtd.2018.04.74.
Trento A, Rodriguez-Fernandez R, Gonzalez-Sanchez M, Gonzalez-Martinez F, Mas V, Vazquez M
Front Microbiol. 2017; 8:2301.
PMID: 29213258
PMC: 5702767.
DOI: 10.3389/fmicb.2017.02301.
Li W, Cao S, Zhang Q, Li J, Zhang S, Wu W
Virol J. 2017; 14(1):133.
PMID: 28720142
PMC: 5516384.
DOI: 10.1186/s12985-017-0799-0.
Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.
Boyoglu-Barnum S, Todd S, Meng J, Barnum T, Chirkova T, Haynes L
J Virol. 2017; 91(10).
PMID: 28275196
PMC: 5411601.
DOI: 10.1128/JVI.02059-16.
Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.
Palomo C, Mas V, Detalle L, Depla E, Cano O, Vazquez M
Antimicrob Agents Chemother. 2016; 60(11):6498-6509.
PMID: 27550346
PMC: 5075053.
DOI: 10.1128/AAC.00842-16.
Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013.
Fagbo S, Garbati M, Hasan R, AlShahrani D, Al-Shehri M, Alfawaz T
J Med Virol. 2016; 89(2):195-201.
PMID: 27430485
PMC: 7166860.
DOI: 10.1002/jmv.24632.
An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein.
Yoon A, Yi K, Chang S, Kim S, Song M, Choi J
PLoS One. 2015; 10(10):e0141312.
PMID: 26512723
PMC: 4626144.
DOI: 10.1371/journal.pone.0141312.
CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.
Chirkova T, Lin S, Oomens A, Gaston K, Boyoglu-Barnum S, Meng J
J Gen Virol. 2015; 96(9):2543-2556.
PMID: 26297201
PMC: 4635495.
DOI: 10.1099/vir.0.000218.
An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.
Boyoglu-Barnum S, Todd S, Chirkova T, Barnum T, Gaston K, Haynes L
Virology. 2015; 483:117-25.
PMID: 25965801
PMC: 4516680.
DOI: 10.1016/j.virol.2015.02.035.
Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.
Boyoglu-Barnum S, Chirkova T, Todd S, Barnum T, Gaston K, Jorquera P
J Virol. 2014; 88(18):10569-83.
PMID: 24990999
PMC: 4178873.
DOI: 10.1128/JVI.01503-14.
Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.
Jones B, Sealy R, Surman S, Portner A, Russell C, Slobod K
Vaccine. 2014; 32(26):3264-73.
PMID: 24721531
PMC: 4049121.
DOI: 10.1016/j.vaccine.2014.03.088.
Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses.
Chirkova T, Boyoglu-Barnum S, Gaston K, Malik F, Trau S, Oomens A
J Virol. 2013; 87(24):13466-79.
PMID: 24089561
PMC: 3838285.
DOI: 10.1128/JVI.01741-13.
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
Robbie G, Criste R, DallAcqua W, Jensen K, Patel N, Losonsky G
Antimicrob Agents Chemother. 2013; 57(12):6147-53.
PMID: 24080653
PMC: 3837853.
DOI: 10.1128/AAC.01285-13.
A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.
Boyoglu-Barnum S, Gaston K, Todd S, Boyoglu C, Chirkova T, Barnum T
J Virol. 2013; 87(20):10955-67.
PMID: 23885067
PMC: 3807296.
DOI: 10.1128/JVI.01164-13.
A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment.
Varada J, Teferedegne B, Crim R, Mdluli T, Audet S, Peden K
Virol J. 2013; 10:195.
PMID: 23767960
PMC: 3686610.
DOI: 10.1186/1743-422X-10-195.
An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting.
van Remmerden Y, Xu F, van Eldik M, Heldens J, Huisman W, Widjojoatmodjo M
Virol J. 2012; 9:253.
PMID: 23114196
PMC: 3514128.
DOI: 10.1186/1743-422X-9-253.
Diagnosis of respiratory syncytial virus infection.
Popow-Kraupp T, Aberle J
Open Microbiol J. 2012; 5:128-34.
PMID: 22262985
PMC: 3258569.
DOI: 10.2174/1874285801105010128.
A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.
Chen M, Chang J, Nason M, Rangel D, Gall J, Graham B
J Immunol Methods. 2010; 362(1-2):180-4.
PMID: 20727896
PMC: 2964415.
DOI: 10.1016/j.jim.2010.08.005.